Clinical Trials Logo

Clinical Trial Summary

It is a single-center, prospective, observational, non-randomized study of newly diagnosed diffuse astrocytoma patients conducted in a tertiary hospital. The investigators conduct an eight-year follow-up, including patients' psychological stress, immune biomarker changes, quality of life, and disease progression of patients towards secondary glioma after the first definite diagnosis. In the first year after diagnosis, patients are followed up four times at 1 month, 3 months, 6 months, and 12 months. After that, patients are followed up semiannually. The study had two cohorts, a high-stress cohort and a low-stress cohort, which are grouped after initial recruitment. Both groups undergo total resection of tumors and received 3 months of standardized treatment with radiotherapy and chemotherapy. Neither participants nor doctors but the researcher can choose which group participants are in. No one knows if one study group is better or worse than the other.


Clinical Trial Description

Diffuse astrocytomas belong to the class of gliomas that represent the most common class of primary malignant human brain tumors in adulthood. After tumor resection, patients still face the possibility of recurrence and even progression to glioblastoma. The immune microenvironment is most likely contributing to their development, but underlying pathomechanisms are only partly understood. The high-level psychological stress can lead to a change in malignant tumors patients' neuroendocrine pathways and correlates with the prognosis outcome. In addition, psychological stress can lead to changes in the immune microenvironment, but if it leads to disease progression in diffuse astrocytoma towards secondary glioma has not been adequately demonstrated. Grouping process: 60 patients are expected to be enrolled. After enrollment, participants will receive regular tumor in situ fluid (fluid within the surgical cavity, TISF) sampling for tumor mutation burden (TMB) analysis and regular MRI. Under the standard of care, participants will receive psychological stress assessment after being diagnosed. according to five psychological scales, and the patients were grouped according to the cut-off value of each scale, the psychological stress of the patients is measured by distress thermometer (DT), perceived stress scale (PSS), anxiety/depression (HADS), VAS stress, and fear of disease progression scale (PoP-Q-SF). Primary study objectives: - To evaluate the proportion of patients with tumor recurrence - To evaluate the changes in immune markers of acute and chronic psychological stress in patients with diffuse astrocytoma after diagnosis. - To analyze the classification of recurrent glioma. Secondary study objectives: - To evaluate the progression-free survival of patients with different psychological stress levels. - To evaluate the overall survival of patients with different psychological stress levels. - To evaluate the quality of life of patients with different psychological stress levels. Exploratory objectives: • To evaluate the effect of managing the patient's psychological stress on the patient's immune microenvironment. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05532969
Study type Observational
Source Henan Provincial People's Hospital
Contact Xingyao Bu
Phone +86037165580295
Email xingyaobu@zzu.edu.cn
Status Not yet recruiting
Phase
Start date December 20, 2022
Completion date December 20, 2026

See also
  Status Clinical Trial Phase
Terminated NCT02764151 - First in Patient Study for PF-06840003 in Malignant Gliomas Phase 1
Completed NCT00994071 - A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors Phase 1
Terminated NCT01502605 - Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas Phase 1
Completed NCT02903784 - Neural Basis of Language Processing N/A
Terminated NCT01044966 - A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma Phase 1/Phase 2
Completed NCT00705198 - Temozolomide All-Case-Registered Surveillance (Designated Drug Use Investigation)(Study P05062) N/A
Completed NCT00165360 - Prolonged Daily Temozolomide for Low-Grade Glioma Phase 2
Active, not recruiting NCT03911388 - HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors Phase 1
Terminated NCT00389090 - A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma Phase 2
Completed NCT00154375 - Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma Phase 3
Completed NCT00001148 - Detecting Malignant Brain Tumor Cells in the Bloodstream During Surgery to Remove the Tumor N/A
Completed NCT03722355 - Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma Phase 3
Recruiting NCT03975829 - Pediatric Long-Term Follow-up and Rollover Study Phase 4
Recruiting NCT05686798 - Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma. Phase 1
Active, not recruiting NCT03739372 - Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma N/A
Recruiting NCT05624736 - Hierarchical Diagnosis for Adult Diffuse Glioma Based on Deep Learning
Recruiting NCT05345002 - All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma Phase 2
Recruiting NCT04028479 - The Registry of Oncology Outcomes Associated With Testing and Treatment
Completed NCT00783393 - SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma (Study P03745) Phase 2
Completed NCT03900689 - Social Determinants of Health in Glioblastoma Population